glp-1 and satiety health: Beyond weight loss in the Ozempic era GLP-1 and Satiety White Paper

The available experimental evidence, which is not yet definitive, proposes several distinct mechanisms that manifest tumor rescue pathways to anti-angiogenic therapies

The best choice depends on your goals and medical history, and its wise to discuss options with a clinician who can personalize a plan and monitor progress

No human clinical trial data quantifies the precise acceleration rate in humans, and the direct translation of the 30% to 50% figure from rodent models to human tendon repair remains unconfirmed by controlled clinical research

reported that GLUT3 is highly expressed in colorectal cancer (CRC), and it is negatively associated with the prognosis of patients with CRC

It also gained approval for a certain type of liver disease (MASH) and reduced risks of cardiovascular death, heart attacks, and strokes in adults with obesity or who are overweight with known heart disease